Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
NCT05725902Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etavopivat in sickle cell disease (SCD), sponsored by Novo Nordisk. Started Mar 2024; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05725902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725902.